Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

More documents

Recommendations

Info

We Innovate Healthcare 34
Avastin’s position as standard of care in first-line mCRC and mNSCLC remains unchallenged Avastin in 1st line and 2nd line mCRC: the only biologic with significant survival benefit • Avastin: only biologic with a statistically significant overall survival (OS) benefit in 1st line and 2nd line mCRC • Avastin: only biologic offering a progression-free survival (PFS) benefit regardless of mutations in K-Ras gene • Avastin: only biologic with a statistically significant OS benefit in K-Ras wild-type patients Avastin remains the best option for the majority of patients with mNSCLC • E2100 and AVAIL: Robustness and consistency of data across endpoints in two phase III studies • The longest median overall survival in first-line non-squamous mNSCLC • ARIES and SAiL data presented at ASCO ‘08 further establish safety / tolerability and broad applicability for non-squamous mNSCLC 35
Page 1 and 2: Clinical Development at Roche: Driv
Page 3 and 4: Our new R&D model: Paradigm changes
Page 5 and 6: Biomarkers A central element throug
Page 7 and 8: Our new R&D model: Paradigm changes
Page 9 and 10: Enhance innovation …by maintainin
Page 11 and 12: Roche Pharma pipeline overview Focu
Page 13 and 14: Major Roche-managed oncology submis
Page 15 and 16: Avastin and cetuximab in combinatio
Page 17 and 18: Avastin and cetuximab in combinatio
Page 19 and 20: Attacking the HER2 pathway from mul
Page 21 and 22: Implementing biomarker strategy for
Page 23 and 24: Key drivers for long term developme
Page 25 and 26: Actemra: The first IL-6 receptor in
Page 27 and 28: CETP Inhibitor R1658 is a unique CE
Page 29 and 30: Taspoglutide: investigational once-
Page 31 and 32: CD20 targeting: new treatment strat
Page 33: Roche R&D opportunities in summary

Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

Create successful ePaper yourself

Delete template?

Save as template?